32896-02-9

Basic information

• Product Name: 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE
• Synonyms: 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE;D90006;3,4-dibromothiophene-2-carbaldehyde;3,4-Dibromothiophene-2-carboxaldehyde 97%;3,4-dibromo-2-Thiophenecarboxaldehyde;3,4-dibromo-2-thiophenealdehyde
• CAS NO: 32896-02-9
• Molecular Formula: C₅H₂Br₂OS
• Molecular Weight: 269.944
• Mol File: 32896-02-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 107-111°C
• Boiling Point: 305.4±37.0 °C(Predicted)
• Appearance: /
• Density: 2.195±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE(32896-02-9)
• EPA Substance Registry System: 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE(32896-02-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 32896-02-9(Hazardous Substances Data)

Usage

Description

3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is a chemical compound belonging to the group of thiophenes, sulfur-containing analogues of benzene. It features two bromine atoms and a formyl group (-CHO), which includes a carbonyl center and a hydrogen atom bonded to the carbon. This organic substance is primarily used in the field of organic synthesis as a building block for creating more complex chemical structures, such as pharmaceuticals and materials. Due to its potential risks and reactivity, it must be handled with appropriate precautions and safety measures.

Uses

Used in Organic Synthesis:
3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is used as a building block for the synthesis of more complex chemical structures, such as pharmaceuticals and materials, due to its unique molecular structure and reactivity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is used as a key intermediate in the development of new drugs and therapeutic agents, leveraging its chemical properties to create novel and effective pharmaceutical compounds.
Used in Material Science:
3,4-DIBROMOTHIOPHENE-2-CARBOXALDEHYDE is utilized in material science for the synthesis of advanced materials with specific properties, such as conductivity, stability, or reactivity, by incorporating its unique molecular structure into the material's composition.

Upstream product

• 3141-26-2 3,4-dibromothiophene 
• 2591-86-8 N-Formylpiperidine 
• 3958-03-0 Tetrabromothiophene 
• 68-12-2 N,N-dimethyl-formamide 
• 3141-25-1 2,3,4-tribromothiophene 
• 5374-05-0 (dichloromethoxy)ethane 

Downstream Products

• 1360605-09-9 3-(3,5-dimethylisoxazol-4-yl)-4-(4-hydroxyphenyl)thiophene-2-carbaldehyde 
• 1360604-75-6 3-(3,5-dimethylisoxazol-4-yl)-4-(4-hydroxyphenyl)thiophene-2-carbaldehyde oxime 
• 125493-06-3 6-bromothieno[3,2-b]thiophene-2-carboxylic acid 
• 1312099-10-7 N-(4-(4-bromo-2-formylthiophen-3-yl)-3-methylphenyl)methanesulfonamide 
• 1312098-23-9 3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)propanoic acid 
• 1312098-74-0 ethyl 3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)propanoate 
• 1312098-72-8 (E)-ethyl 3-(4-(4-chloro-2-methoxyphenyl)-3-(4-hydroxyphenyl)thiophen-2-yl)acrylate 
• 1353572-40-3 4-bromo-3-(4-hydroxyphenyl)thiophene-2-carbaldehyde 
• 1312098-71-7 4-bromo-3-(4-hydroxyphenyl)thiophene-2-carbaldehyde 
• 25121-83-9 3-bromothieno<3,2-b>thiophene 
• 1098608-28-6 ethyl 6-bromothieno[3,2-b]thiophene-2-carboxylate 
• 189745-63-9 4-(3,4-dibromothien-2-yl)methanol-1-trityl-imidazole 
• 189745-66-2 (3,4-dibromo-thiophen-2-yl)-(1-trityl-1H-imidazol-4-yl)-methanone 

Relevant articles and documents

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

Isomeric effect of fluorene-based fused-ring electron acceptors to achieve high-efficiency organic solar cells

Acceptor-donor-acceptor (A-D-A) non-fullerene electron acceptors (NFEAs) using ladder-type donor structures have become the dominant n-type materials for achieving high-efficiency OSCs. In this work, two isomeric fluorene-based ladder-type structures FCTT (TT-C-F-C-TT) and FTCT (T-C-TFT-C-T) have been designed and synthesized. These two isomeric donors with the different fused-ring arrangement, molecular geometry, and side-chain placement were end-capped with the FIC acceptors to form two NFEAs FCTT-FIC and FTCT-FIC isomeric materials. Compared to FTCT-FIC using the thiophene (T)-terminal donor, FCTT-FIC with the thienothiophene (TT)-terminal donor has more evenly distributed side chains on both sides of the backbone and less steric hindrance near the FIC acceptors, which enables stronger antiparallel π-π packing among the end-groups to create a channel for efficient electron transport, as evidenced by the thin-film GIWAXS measurements. FCTT-FIC displayed a larger optical bandgap and deeper-lying energy levels than its FTCT-FIC isomer. Compared to the PBDB-T:FTCT-FIC device, the PBDB-T:FCTT-FIC device showed a higher PCE of 10.32% with an enhanced Jsc of 19.63 mA cm-2 and an FF of 69.14%. A PM6:FCTT-FIC device using PM6 as a p-type polymer achieved the highest PCE of 12.23%. By introducing PC71BM as the second acceptor to enhance the absorption at shorter wavelengths, optimize the morphology and facilitate electron transport, the ternary-blend PM6:FCTT-FIC:PC71BM (1 : 1 : 0.5 in wt%) device yielded the highest PCE of 13.37% with a Voc of 0.92 V, a higher Jsc of 19.86 mA cm-2, and an FF of 73.2%. This result demonstrated that the TT-terminal ladder-type donor is generally a better molecular design than the corresponding T-terminal ladder-type isomer for the development of new A-D-A NFEAs.

Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists

The optimization of a series of thieno[3,2-b]thiophene-2-carboxylic acid derivatives for agonist activity against the GPR35 is reported. Compounds were optimized to achieve β-arrestin-biased agonism for developing probe molecules that may be useful for elucidating the biology and physiology of GPR35. Compound 13 was identified to the most potent GPR35 agonist, and compounds 30 and 36 exhibited the highest efficacy to cause β-arrestin translocation.